
Alpha Profiles · Company Profile
Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease.
https://registry.alpha.ac/companies/acumen-pharmaceuticals-inc
- Entity
- Public listing published
- Primary listing
- NASDAQ: ABOS
- Verification
- Partially verified
- Last reviewed
- 2026-09-12T21:32:05.800844+00:00
Overview
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. T
Source record
Alpha canonical company public projection
Supports Company identity, Published leadership, Entity status boundary
Reviewed 2026-09-12T21:32:05.800844+00:00
